Galderma Shares Slump After FDA Turns Down Botox Rival Relfydess
Bloomberg 2026-07-01 07:54:42
Context: Galderma Group AG, a Swiss dermatology firm, saw its shares decline significantly after announcing that the US Food and Drug Administration had rejected its Botox rival treatment, Relfydess. This development had a substantial impact on the company's stock performance. The rejection marks a setback for Galderma in its efforts to compete with Botox.
Key Facts
- Galderma Group AG shares experienced their largest decline in more than a year following the FDA's decision to turn down Relfydess, a treatment that was being positioned as a rival to Botox.
- The FDA's rejection of Relfydess is a significant setback for Galderma, as the company had been seeking to expand its presence in the dermatology market with this new treatment option.
- Relfydess was intended to compete directly with Botox, a popular and widely used treatment for various cosmetic and therapeutic applications, and its rejection leaves Galderma without a direct competitor in this space.